Stock MEDCL MEDINCELL S.A.
Add to a list
To use this feature you must be a member
Log inSign up

News MedinCell S.A.

Equities

MEDCL

FR0004065605

Real-time Euronext Paris
Other stock markets
 10:17:11 2024-06-12 am EDT 		5-day change 1st Jan Change
14.76 EUR 0.00% Intraday chart for MedinCell S.A. -5.63% +105.00%
Jun. 10 Transcript : MedinCell S.A., 2024 Earnings Call, Jun 10, 2024
Jun. 10 Medincell: a 'new era' after a 'pivotal' 2023 CF

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
MedinCell S A : Inside Information / Other news releases
PU
Medincell Joins the Euronext Tech Leaders
BU
Transcript : MedinCell S.A., 2024 Earnings Call, Jun 10, 2024
Medincell: a 'new era' after a 'pivotal' 2023
CF
Medincell Publishes Its Consolidated Annual Financial Results
BU
Medincell: Publication of the Financial Results for the 2023-2024 Fiscal Year and Videoconference on Monday, June 10, 2024
BU
Medincell’s Partner Teva presented New Data Providing Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) from Invega Sustenna® (paliperidone palmitate)
BU
Medincell: Update of the 2024 Financial Calendar
BU
Medincell to Present at the 2024 Jefferies Global Healthcare Conference, June 4 to 6, 2024, New York
BU
Medincell: share price falls after disappointing clinical study
CF
Transcript : MedinCell S.A. - Special Call
Medincell Provides Update on Phase 3 mdc-CWM Clinical Trial
BU
Medincell Provides Update on Phase 3 mdc-CWM Clinical Trial
CI
Medincell to Host Videoconference on May 15, 2024, at 10:30 AM CEST to Discuss Company's Latest News, Outlook, and R&D Activities
BU
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-749 as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
AQ
Medincell: share price rises on resumption of trading
CF
CAC40: remains in green in a neglected market
CF
Medincell: positive results in schizophrenia
CF
Medincell Listing Temporarily Suspended on Euronext Paris
MT
Teva and Medincell's schizophrenia drug meets main goal of late-stage study
RE
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MEDCL Stock
  4. News MedinCell S.A.